-
公开(公告)号：US20120078028A1
公开(公告)日：2012-03-29
申请号：US13249111
申请日：2011-09-29
申请人： Daulet SATPAYEV , Robert Kendall Morrison , Karen Jane Meyrick Morrison , Jean Gudas , Aya Jakobovits , Michael Torgov , Zili An
发明人： Daulet SATPAYEV , Robert Kendall Morrison , Karen Jane Meyrick Morrison , Jean Gudas , Aya Jakobovits , Michael Torgov , Zili An
IPC分类号： A61N5/00 , A61K39/395 , A61P35/00 , C07K16/28
CPC分类号： A61K47/6851 , A61K47/6801 , A61K47/6803 , A61K47/6811 , A61K47/6855 , A61K47/6857 , A61K47/6859 , A61K47/6861 , A61K47/6889 , A61K2039/505 , A61N5/1001 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K2317/14 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/92
摘要： Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
摘要翻译： 本文描述了结合191P4D12蛋白及其变体的抗体药物偶联物（ADC）。 191P4D12在正常成人组织中表现出组织特异性表达，并且在表I中列出的癌症中异常表达。因此，本发明的ADC提供了用于治疗癌症的治疗组合物。
-
公开(公告)号：US08637642B2
公开(公告)日：2014-01-28
申请号：US13249111
申请日：2011-09-29
申请人： Daulet Satpayev , Robert Kendall Morrison , Karen Jane Meyrick Morrison , Jean Gudas , Aya Jakobovits , Michael Torgov , Zili An
发明人： Daulet Satpayev , Robert Kendall Morrison , Karen Jane Meyrick Morrison , Jean Gudas , Aya Jakobovits , Michael Torgov , Zili An
CPC分类号： A61K47/6851 , A61K47/6801 , A61K47/6803 , A61K47/6811 , A61K47/6855 , A61K47/6857 , A61K47/6859 , A61K47/6861 , A61K47/6889 , A61K2039/505 , A61N5/1001 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K2317/14 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/92
摘要： Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
摘要翻译： 本文描述了结合191P4D12蛋白及其变体的抗体药物偶联物（ADC）。 191P4D12在正常成人组织中表现出组织特异性表达，并且在表I中列出的癌症中异常表达。因此，本发明的ADC提供了用于治疗癌症的治疗组合物。
-
3.发明授权公开(公告)号：US08609092B2
公开(公告)日：2013-12-17
申请号：US13022905
申请日：2011-02-08
申请人： Michael Torgov , Robert Kendall Morrison , Aya Jakobovits , Jean Gudas , Zili An
发明人： Michael Torgov , Robert Kendall Morrison , Aya Jakobovits , Jean Gudas , Zili An
IPC分类号： A61K39/395 , A61P35/00 , C07K16/18 , A61N5/00 , C12N5/09
CPC分类号： A61K47/48607 , A61K39/39558 , A61K47/6811 , A61K47/6849 , A61K47/6861 , A61K2039/505 , C07K16/28 , C07K16/3038 , C07K2317/21 , C07K2317/56 , C07K2317/92
摘要： Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
摘要翻译： 本文描述了结合161P2F10B蛋白的抗体药物偶联物（ADC）。 161P2F10B在正常成人组织中表现出组织特异性表达，并且在表I中列出的癌症中异常表达。因此，本发明的ADC提供了用于治疗癌症的治疗组合物。
-
公开(公告)号：US20090010945A1
公开(公告)日：2009-01-08
申请号：US10591743
申请日：2005-03-02
申请人： Stephen C. Alley , Michael Torgov , Michael Sun
发明人： Stephen C. Alley , Michael Torgov , Michael Sun
CPC分类号： C07K16/2878 , A61K47/6803 , A61K47/6849 , A61K2039/505 , Y02A50/412
摘要： A protein containing one or more activatable groups, e.g., an antibody, is subjected to partial or complete reduction of one or more such bonds to form reactive groups; the resulting protein is reacted with a drug which is reactive with some of the reactive groups, such as certain radiometals, chelating agents, and toxins, so as to form a conjugate useful in, e.g., in vitro diagnosis, in vivo imaging, and therapy.
摘要翻译： 含有一个或多个可激活基团（例如抗体）的蛋白质被部分或完全还原一个或多个这样的键以形成反应性基团; 所产生的蛋白质与与某些反应性基团如某些放射性金属螯合剂和毒素反应的药物反应，以便形成用于例如体外诊断，体内成像和治疗的缀合物 。
-
公开(公告)号：US20110097322A1
公开(公告)日：2011-04-28
申请号：US12916294
申请日：2010-10-29
申请人： Stephen C. Alley , Michael Torgov , Michael Sun
发明人： Stephen C. Alley , Michael Torgov , Michael Sun
IPC分类号： A61K39/395 , A61P35/00 , A61P37/02 , A61P31/00
CPC分类号： C07K16/2878 , A61K47/6803 , A61K47/6849 , A61K2039/505 , Y02A50/412
摘要： A protein containing one or more activatable groups, e.g., an antibody, is subjected to partial or complete reduction of one or more such bonds to form reactive groups; the resulting protein is reacted with a drug which is reactive with some of the reactive groups, such as certain radiometals, chelating agents, and toxins, so as to form a conjugate useful in, e.g., in vitro diagnosis, in vivo imaging, and therapy.
摘要翻译： 含有一个或多个可激活基团（例如抗体）的蛋白质被部分或完全还原一个或多个这样的键以形成反应性基团; 所产生的蛋白质与与某些反应性基团如某些放射性金属螯合剂和毒素反应的药物反应，以便形成用于例如体外诊断，体内成像和治疗的缀合物 。
-
公开(公告)号：US08846873B2
公开(公告)日：2014-09-30
申请号：US13355366
申请日：2012-01-20
申请人： Feng Xiao , Xiao-Chi Jia , Meina Liang , Orit Foord , Scott Klakamp , Kam Fai Tse , Vincent A. Pollack , Luca Rastelli , John Herrmann , Henri Lichenstein , Michael Jeffers , William LaRochelle , Gulshan Ara , Peter Mezes , Andrei Chapoval , Cyrus Karkaria , Michael Torgov , Juan Davagnino
发明人： Feng Xiao , Xiao-Chi Jia , Meina Liang , Orit Foord , Scott Klakamp , Kam Fai Tse , Vincent A. Pollack , Luca Rastelli , John Herrmann , Henri Lichenstein , Michael Jeffers , William LaRochelle , Gulshan Ara , Peter Mezes , Andrei Chapoval , Cyrus Karkaria , Michael Torgov , Juan Davagnino
CPC分类号： C07K16/3053 , A61K47/6803 , A61K47/6849 , A61K47/6851 , A61K2039/505 , A61K2039/545 , C07K16/2809 , C07K16/30 , C07K16/3061 , C07K2317/21 , C07K2317/31 , C07K2317/565 , C07K2317/62 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/77 , C07K2317/94
摘要： The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.
摘要翻译： 本发明提供了完全与GPNMB结合的人单克隆抗体及其应用。 提供了编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列。 本发明还提供了包含抗GPNMB抗体的免疫缀合物和使用这种免疫缀合物的方法。 本发明还提供了包含抗GPNMB抗体组分和抗-CD3组分的双特异性抗体，以及使用这种双特异性抗体的方法。
-
公开(公告)号：US20130022597A1
公开(公告)日：2013-01-24
申请号：US13355366
申请日：2012-01-20
申请人： Meina Liang , Orit Foord , Scott Klakamp , Vincent A. Pollack , Luca Rastelli , John Herrmann , Henri Lichenstein , Michael Jeffers , William LaRochelle , Peter Mezes , Andrei Chapoval , Cyrus Karkaria , Michael Torgov , Juan Davagnino
发明人： Feng Xiao , Xiao-Chi Jia , Meina Liang , Orit Foord , Scott Klakamp , Kam Fai Tse , Vincent A. Pollack , Luca Rastelli , John Herrmann , Henri Lichenstein , Michael Jeffers , William LaRochelle , Gulshan Ara , Peter Mezes , Andrei Chapoval , Cyrus Karkaria , Michael Torgov , Juan Davagnino
IPC分类号： A61K39/395 , C12N15/13 , C40B30/04 , C12N15/63 , C12N1/21 , C12N5/10 , C07K16/18 , A61P35/00
CPC分类号： C07K16/3053 , A61K47/6803 , A61K47/6849 , A61K47/6851 , A61K2039/505 , A61K2039/545 , C07K16/2809 , C07K16/30 , C07K16/3061 , C07K2317/21 , C07K2317/31 , C07K2317/565 , C07K2317/62 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/77 , C07K2317/94
摘要： The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.
摘要翻译： 本发明提供了完全与GPNMB结合的人单克隆抗体及其应用。 提供了编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列。 本发明还提供了包含抗GPNMB抗体的免疫缀合物和使用这种免疫缀合物的方法。 本发明还提供了包含抗GPNMB抗体组分和抗-CD3组分的双特异性抗体，以及使用这种双特异性抗体的方法。
-
公开(公告)号：US07837980B2
公开(公告)日：2010-11-23
申请号：US10591743
申请日：2005-03-02
申请人： Stephen C. Alley , Michael Torgov , Michael Sun
发明人： Stephen C. Alley , Michael Torgov , Michael Sun
CPC分类号： C07K16/2878 , A61K47/6803 , A61K47/6849 , A61K2039/505 , Y02A50/412
摘要： A protein containing one or more activatable groups, e.g., an antibody, is subjected to partial or complete reduction of one or more such bonds to form reactive groups; the resulting protein is reacted with a drug which is reactive with some of the reactive groups, such as certain radiometals, chelating agents, and toxins, so as to form a conjugate useful in, e.g., in vitro diagnosis, in vivo imaging, and therapy.
摘要翻译： 含有一个或多个可激活基团（例如抗体）的蛋白质被部分或完全还原一个或多个这样的键以形成反应性基团; 所产生的蛋白质与与某些反应性基团如某些放射性金属螯合剂和毒素反应的药物反应，以便形成用于例如体外诊断，体内成像和治疗的缀合物 。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.034 秒)
